Acalabrutinib (ACP-196) is a highly selective, Bruton's tyrosine kinase (BTK) inhibitor developed to minimize off-target activity with minimal effects on TEC, EGFR, or ITK signaling.1
As of July 2022, more CLL patients start on CALQUENCE (acalabrutinib) than any other targeted therapy.
Please visit www.clinicaltrials.gov to learn more about the ongoing phase 1, 2 and 3 programs.
1 Covey T, et al. Presentation at the 2015 annual AACR meeting. Abstract 2596.
2 Byrd JC, et al. N Engl J Med. 2016;374(4):323-332.